MedTrace Logo

Study of Ipilimumab in the Immune System

NCT01715077 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-08-13

No results posted yet for this study

Summary

Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.

Conditions

  • Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma

Interventions

DRUG

Ipilimumab at 3 mg/kg dose

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Anthony Joshua, M.D · UHN-Princess Margaet Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715077 on ClinicalTrials.gov